CJC-1295 / Ipamorelin pairs two complementary peptides that stimulate the body's own growth hormone production. CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH) that signals the pituitary to release growth hormone. Ipamorelin is a selective growth hormone secretagogue that acts on a separate receptor to reinforce that signal. Combined, they produce a stronger, more sustained pulse than either peptide alone. This is one of the most studied growth-hormone-optimization protocols Dr. Taylor prescribes.

The two peptides work through different pituitary receptors to reinforce the body's natural, pulsatile growth hormone release, which in turn raises IGF-1. Because ipamorelin is highly selective, it does this with minimal effect on cortisol, prolactin, or appetite. Patients typically pursue it for sleep quality, recovery, and body composition rather than dramatic short-term change.

Adults interested in growth hormone optimization as part of a longevity or recomposition protocol, people focused on sleep quality and recovery, those working on body composition who want a favorable side-effect profile, and patients who want the combined effect of two complementary mechanisms.

Many patients report changes in sleep quality within the first two to three weeks. Body composition and recovery changes are typically reported later, often in the six-to-eight-week range, as sustained signaling builds. Dosing is personalized by Dr. Taylor after your intake.

Commonly reported side effects include water retention, tingling or numbness in the extremities, injection site reactions, headache, flushing, transient lightheadedness, and a temporary increase in hunger. This protocol is not appropriate with active or prior cancer, during pregnancy or breastfeeding, with pituitary tumors or disorders, with diabetic retinopathy, or with uncontrolled diabetes. CJC-1295 and ipamorelin are not FDA-approved and are prescribed off-label under physician supervision after intake and informed consent.